A Joint Model Based on Longitudinal CA125 in Ovarian Cancer to Predict Recurrence

References

• Gupta D , LisCG. Role of CA125 in predicting ovarian cancer survival–a review of the epidemiological literature. J. Ovarian Res.2, 13 (2009).
   PubMed Web of Science ®Google Scholar
• Jemal A , BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J. Clin.61(2), 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• Gadducci A , CosioS, ZolaP, LandoniF, MagginoT, SartoriE. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int. J. Gynecol. Cancer17(1), 21–31 (2007).
   Web of Science ®Google Scholar
• Gadducci A , CosioS, ContePF, GenazzaniAR. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit. Rev. Oncol. Hematol.55(2), 153–166 (2005).
   Web of Science ®Google Scholar
• Oza AM , CastonguayV, TsorefDet al. Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr. Oncol.18(Suppl. 2), S20–S27 (2011).
   Google Scholar
• Cox DR . Regression models and life-tables. J. R. Stat. Soc. B34(2), 187–220 (1972).
   Google Scholar
• Gadducci A , CosioS, FanucchiA, NegriS, CristofaniR, GenazzaniAR. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol. Oncol.93(1), 131–136 (2004).
   Web of Science ®Google Scholar
• Riedinger JM , WafflartJ, RicolleauGet al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann. Oncol.17(8), 1234–1238 (2006).
   Web of Science ®Google Scholar
• Han LY , KaravasilisV, HagenTet al. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. Eur. J. Cancer46(8), 1359–1364 (2010).
   Web of Science ®Google Scholar
• Mano A , FalcaoA, GodinhoIet al. CA–125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol. Oncol.97(2), 529–534 (2005).
   Web of Science ®Google Scholar
• Prat A , PareraM, AdamoBet al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann. Oncol.20(2), 294–297 (2009).
   PubMed Web of Science ®Google Scholar
• Kang WD , ChoiHS, KimSM. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. Gynecol. Oncol.116(1), 57–60 (2010).
   PubMed Web of Science ®Google Scholar
• Van Altena AM , KolwijckE, SpanjerMJ, HendriksJC, MassugerLF, De HulluJA. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. Gynecol. Oncol.119(2), 265–269 (2010).
   PubMed Web of Science ®Google Scholar
• Chiang A , ChenJ, ChungY, HuangH, LiouW, ChangC. A longitudinal analysis with CA125 to predict overall survival in patients with ovarian cancer. J. Gynecol. Oncol.25(1), 1–7 (2014).
   Web of Science ®Google Scholar
• Rizopoulos D . Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data. Biometrics67(3), 819–829 (2011).
   PubMed Web of Science ®Google Scholar
• Rustin GJ , Van Der BurgME, GriffinCLet al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet376(9747), 1155–1163 (2010).
   PubMed Web of Science ®Google Scholar
• Team RDC . R: a language and environment of statistical computing. R Foundation for Statistical Computing : Vienna, Austria (2010). www.gbif.org/resource/81287
   Google Scholar
• Bristow RE , Del CarmenMG, PannuHKet al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol. Oncol.90(3), 519–528 (2003).
   Web of Science ®Google Scholar
• Chang C , ChowSN, HuY. Age of menopause of Chinese women in Taiwan. Int. J. Gynaecol. Obstet.49(2), 191–192 (1995).
   Web of Science ®Google Scholar
• Do KA , TreloarSA, PandeyaNet al. Predictive factors of age at menopause in a large Australian twin study. Hum. Biol.70(6), 1073–1091 (1998).
   PubMed Web of Science ®Google Scholar
• Polterauer S , VergoteI, ConcinNet al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int. J. Gynecol. Cancer22(3), 380–385 (2012).
   PubMed Web of Science ®Google Scholar
• Joint Model, Version 2. www.math.nsysu.edu.tw/~cchang/predict_survival/version2/
   Google Scholar
• Sankaranarayanan R , FerlayJ. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol.20(2), 207–225 (2006).
   PubMed Web of Science ®Google Scholar
• Hess LM , RongN, MonahanPO, GuptaP, ThomaskuttyC, MateiD. Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis. Cancer116(22), 5251–5260 (2010).
   PubMed Web of Science ®Google Scholar
• Ozols RF . Treatment goals in ovarian cancer. Int. J. Gynecol. Cancer15(Suppl. 1), 3–11 (2005).
   PubMed Web of Science ®Google Scholar
• Rustin GJ . Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann. Oncol.22(Suppl. 8), viii45–viii48 (2011).
   PubMedGoogle Scholar
• Pignata S , CannellaL, LeopardoD, BruniGS, FacchiniG, PisanoC. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann. Oncol.22(Suppl. 8) viii40–viii44 (2011).
   Google Scholar
• Markman M , LiuPY, RothenbergML, MonkBJ, BradyM, AlbertsDS. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J. Clin. Oncol.24(9), 1454–1458 (2006).
   Web of Science ®Google Scholar
• Ueland FR , DesimoneCP, SeamonLGet al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet. Gynecol.117(6), 1289–1297 (2011).
   PubMed Web of Science ®Google Scholar
• Nolen BM , LokshinAE. Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol. Diagn. Ther.17(3), 139–146 (2013).
   PubMed Web of Science ®Google Scholar